Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant

Irene C Kuo, Yumi Imai, Carol Shum, Daniel F. Martin, Baruch D. Kuppermann, Todd P. Margolis

Research output: Contribution to journalArticle

Abstract

PURPOSE: To determine whether cytomegalovirus (CMV) retinitis that responded poorly to intravenous ganciclovir therapy but responded to the ganciclovir implant was caused by virus with resistance mutations in the viral UL97 and UL54 genes. DESIGN: Retrospective chart review and laboratory-based experimental study. METHODS: Regions of the CMV UL97 and UL54 were amplified from the vitreous and analyzed for resistant mutations by a combination of DNA sequencing and restriction digestion. Vitreous from patients with AIDS and retinal infections other than CMV retinitis served as negative controls. RESULTS: We amplified all target regions of UL97 DNA and most target regions of UL54 DNA from eight eyes with CMV retinitis. In one eye we found a ganciclovir resistance mutation at base 1781 of the UL97 gene, predicting an alanine to valine mutation at codon 594. In a second eye we found a ganciclovir resistance mutation at base 2960 of the UL54 gene, predicting an alanine to glycine mutation at codon 987. In two additional eyes, both from patients with bilateral retinitis, we found UL54 mutations that are likely to confer resistance to ganciclovir but have not been previously described. In both of these patients the UL54 genotype differed between the two diseased eyes. CONCLUSIONS: Failure to control CMV retinitis with intravenous ganciclovir does not necessarily imply infection with a virus having a known mutation that confers drug resistance. The ganciclovir implant can be an effective therapy for CMV retinitis caused by virus with certain UL97 and UL54 resistance mutations. Cytomegalovirus UL54 genotypes can differ between eyes in patients with bilateral retinitis.

Original languageEnglish (US)
Pages (from-to)20-25
Number of pages6
JournalAmerican Journal of Ophthalmology
Volume135
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Cytomegalovirus Retinitis
Ganciclovir
Mutation
Retinitis
Viruses
Cytomegalovirus
Codon
Alanine
Genotype
Genes
Eye Diseases
DNA
Valine
Infection
DNA Sequence Analysis
Drug Resistance
Glycine
Digestion
Acquired Immunodeficiency Syndrome

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant. / Kuo, Irene C; Imai, Yumi; Shum, Carol; Martin, Daniel F.; Kuppermann, Baruch D.; Margolis, Todd P.

In: American Journal of Ophthalmology, Vol. 135, No. 1, 01.01.2003, p. 20-25.

Research output: Contribution to journalArticle

Kuo, Irene C ; Imai, Yumi ; Shum, Carol ; Martin, Daniel F. ; Kuppermann, Baruch D. ; Margolis, Todd P. / Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant. In: American Journal of Ophthalmology. 2003 ; Vol. 135, No. 1. pp. 20-25.
@article{f0f4b13ca33c4a10a2a37cd7be1b7549,
title = "Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant",
abstract = "PURPOSE: To determine whether cytomegalovirus (CMV) retinitis that responded poorly to intravenous ganciclovir therapy but responded to the ganciclovir implant was caused by virus with resistance mutations in the viral UL97 and UL54 genes. DESIGN: Retrospective chart review and laboratory-based experimental study. METHODS: Regions of the CMV UL97 and UL54 were amplified from the vitreous and analyzed for resistant mutations by a combination of DNA sequencing and restriction digestion. Vitreous from patients with AIDS and retinal infections other than CMV retinitis served as negative controls. RESULTS: We amplified all target regions of UL97 DNA and most target regions of UL54 DNA from eight eyes with CMV retinitis. In one eye we found a ganciclovir resistance mutation at base 1781 of the UL97 gene, predicting an alanine to valine mutation at codon 594. In a second eye we found a ganciclovir resistance mutation at base 2960 of the UL54 gene, predicting an alanine to glycine mutation at codon 987. In two additional eyes, both from patients with bilateral retinitis, we found UL54 mutations that are likely to confer resistance to ganciclovir but have not been previously described. In both of these patients the UL54 genotype differed between the two diseased eyes. CONCLUSIONS: Failure to control CMV retinitis with intravenous ganciclovir does not necessarily imply infection with a virus having a known mutation that confers drug resistance. The ganciclovir implant can be an effective therapy for CMV retinitis caused by virus with certain UL97 and UL54 resistance mutations. Cytomegalovirus UL54 genotypes can differ between eyes in patients with bilateral retinitis.",
author = "Kuo, {Irene C} and Yumi Imai and Carol Shum and Martin, {Daniel F.} and Kuppermann, {Baruch D.} and Margolis, {Todd P.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S0002-9394(02)01758-0",
language = "English (US)",
volume = "135",
pages = "20--25",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant

AU - Kuo, Irene C

AU - Imai, Yumi

AU - Shum, Carol

AU - Martin, Daniel F.

AU - Kuppermann, Baruch D.

AU - Margolis, Todd P.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - PURPOSE: To determine whether cytomegalovirus (CMV) retinitis that responded poorly to intravenous ganciclovir therapy but responded to the ganciclovir implant was caused by virus with resistance mutations in the viral UL97 and UL54 genes. DESIGN: Retrospective chart review and laboratory-based experimental study. METHODS: Regions of the CMV UL97 and UL54 were amplified from the vitreous and analyzed for resistant mutations by a combination of DNA sequencing and restriction digestion. Vitreous from patients with AIDS and retinal infections other than CMV retinitis served as negative controls. RESULTS: We amplified all target regions of UL97 DNA and most target regions of UL54 DNA from eight eyes with CMV retinitis. In one eye we found a ganciclovir resistance mutation at base 1781 of the UL97 gene, predicting an alanine to valine mutation at codon 594. In a second eye we found a ganciclovir resistance mutation at base 2960 of the UL54 gene, predicting an alanine to glycine mutation at codon 987. In two additional eyes, both from patients with bilateral retinitis, we found UL54 mutations that are likely to confer resistance to ganciclovir but have not been previously described. In both of these patients the UL54 genotype differed between the two diseased eyes. CONCLUSIONS: Failure to control CMV retinitis with intravenous ganciclovir does not necessarily imply infection with a virus having a known mutation that confers drug resistance. The ganciclovir implant can be an effective therapy for CMV retinitis caused by virus with certain UL97 and UL54 resistance mutations. Cytomegalovirus UL54 genotypes can differ between eyes in patients with bilateral retinitis.

AB - PURPOSE: To determine whether cytomegalovirus (CMV) retinitis that responded poorly to intravenous ganciclovir therapy but responded to the ganciclovir implant was caused by virus with resistance mutations in the viral UL97 and UL54 genes. DESIGN: Retrospective chart review and laboratory-based experimental study. METHODS: Regions of the CMV UL97 and UL54 were amplified from the vitreous and analyzed for resistant mutations by a combination of DNA sequencing and restriction digestion. Vitreous from patients with AIDS and retinal infections other than CMV retinitis served as negative controls. RESULTS: We amplified all target regions of UL97 DNA and most target regions of UL54 DNA from eight eyes with CMV retinitis. In one eye we found a ganciclovir resistance mutation at base 1781 of the UL97 gene, predicting an alanine to valine mutation at codon 594. In a second eye we found a ganciclovir resistance mutation at base 2960 of the UL54 gene, predicting an alanine to glycine mutation at codon 987. In two additional eyes, both from patients with bilateral retinitis, we found UL54 mutations that are likely to confer resistance to ganciclovir but have not been previously described. In both of these patients the UL54 genotype differed between the two diseased eyes. CONCLUSIONS: Failure to control CMV retinitis with intravenous ganciclovir does not necessarily imply infection with a virus having a known mutation that confers drug resistance. The ganciclovir implant can be an effective therapy for CMV retinitis caused by virus with certain UL97 and UL54 resistance mutations. Cytomegalovirus UL54 genotypes can differ between eyes in patients with bilateral retinitis.

UR - http://www.scopus.com/inward/record.url?scp=0037215339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037215339&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(02)01758-0

DO - 10.1016/S0002-9394(02)01758-0

M3 - Article

C2 - 12504692

AN - SCOPUS:0037215339

VL - 135

SP - 20

EP - 25

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 1

ER -